工业大麻概念12日盘中发力拉升，截至发稿，福安药业涨超15%，莱茵生物涨停，晨光生物涨近7%， 康恩贝、福日电子涨约6%。 据悉，工业大麻是大麻属原植物及其提取产品，其特点是四氢大麻酚含量低于0.3%且不显示精神活 性。工业大麻的籽、花叶、皮、杆、根可应用于纺织、食品、日化、医药等领域。据Mordor Intelligence的预测，全球工业大麻市场规模将从2023年的22.1亿美元快速增长至2028年的49.7亿美元， 未来五年CAGR达17.56%。 （文章来源：证券时报网） 消息面上，据报道，特朗普周一在新闻发布会上表示：正在考虑重新分类大麻的危险等级，将在未来几 周内做出决定。另据此前报道，特朗普正在考虑将大麻改为危险性较低的药物分类。根据美国联邦法 律，大麻目前被归类为一级管制药物，与可卡因同属一类。 受此消息提振，美股市场大麻相关股票周一表现强劲。Canopy Growth涨超26%，Tilray Brands大涨超 40%，Cronos Group则跳涨逾14%并创下52周新高。 ...

Core Viewpoint - ST Longjin is facing delisting due to a net profit loss in the recently disclosed 2024 annual report and revenue falling below 300 million, triggering delisting conditions [2][14]. Company Overview - Longjin Pharmaceutical was established in September 1996, focusing on the research, production, and sales of modern traditional Chinese medicine and high-end chemical generics [2]. - The company’s representative products include injection of Ligusticum Chuanxiong, injection of fibrinolytic enzyme, and injection of Bivalirudin, with Ligusticum Chuanxiong being the core product [2]. Stock Performance - Longjin Pharmaceutical was listed in 2015 during a bull market, with its stock price peaking at 135 yuan before experiencing a significant decline, dropping to around 6 yuan within two years [2]. - In 2019, the company invested 15 million yuan to acquire a 51% stake in Yunnan Muya Agricultural Technology Co., which focuses on large-scale industrial hemp cultivation, leading to a stock price surge from 5 yuan to 23.5 yuan in two months [4]. - The stock was heavily speculated upon due to the industrial hemp concept, achieving multiple trading halts in 2021, earning the title of the "first industrial hemp stock" [4]. Financial Performance - From 2021 to 2024, Longjin Pharmaceutical's revenue showed a drastic decline: 702.5 million, 123 million, 86.62 million, and 66.48 million respectively, with net profits of 3.093 million, -56.12 million, -70.94 million, and -41.44 million, indicating three consecutive years of losses [7]. - The company was placed under delisting risk warning by the Shenzhen Stock Exchange in the previous year due to a negative net profit and revenue below 100 million [8]. Recent Developments - Following the delisting risk warning, Longjin Pharmaceutical's stock faced a series of trading halts, with the price plummeting to around 1 yuan after multiple trading suspensions [9][11]. - Currently, there are nearly 30,000 shareholders, many of whom are stuck with high-priced shares and reluctant to sell [14]. Industry Context - The number of listed companies in A-shares has exceeded 5,000, with an increasing number of delistings each year, highlighting the importance of avoiding poorly performing stocks [16].